Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 7:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 2,224 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ADD Clear all
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

NCT04467983
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Denosumab Injection, Abaloparatide
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
45 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 7:37 PM EDT
Recruiting Phase 3 Interventional

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

NCT05863195
View directory record Official record
Conditions
Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
Interventions
Bevacizumab, Capecitabine, Cetuximab, Computed Tomography, Floxuridine, Fluorouracil, Implantation, Intrahepatic Infusion Procedure, Irinotecan, Leucovorin, Magnetic Resonance Imaging, Oxaliplatin, Panitumumab, Single Photon Emission Computed Tomography
Biological · Drug · Procedure
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
62
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 28, 2026, 7:37 PM EDT
Completed Phase 2 Interventional Results available

PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations

NCT03265119
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
AEVI-001, Placebo
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
6 Years to 17 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Wayne, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Oct 28, 2026, 7:37 PM EDT
Recruiting Phase 1 Interventional

A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease

NCT06164730
View directory record Official record
Conditions
Heterozygous Familial Hypercholesterolemia, Premature Coronary Heart Disease
Interventions
VERVE-102
Drug
Lead sponsor
Verve Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
10
States / cities
Dothan, Alabama • Pomona, California • Boca Raton, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 28, 2026, 7:37 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia

NCT01623167
View directory record Official record
Conditions
Severe Aplastic Anemia
Interventions
Cohort 1: hATG, CsA, EPAG Day 14 to Month 6, Cohort 2: hATG, CsA, EPAG Day 14 to Month 3, Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6, Extension Cohort
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 95 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 28, 2026, 7:37 PM EDT
Recruiting Not applicable Interventional

Regulating Emotions Like An eXpert Among Adolescents With ADHD

NCT06725186
View directory record Official record
Conditions
RELAX Telehealth Intervention, Psychoeducational Waitlist Control, EMI Smartphone App Pilot
Interventions
RELAX, Psychoeducational Materials
Behavioral
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
11 Years to 16 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Blacksburg, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 28, 2026, 7:37 PM EDT
Withdrawn Phase 2 Interventional

Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer

NCT04989283
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Superior Sulcus Lung Carcinoma
Interventions
Atezolizumab, Biopsy, Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Etoposide, External Beam Radiation Therapy, Magnetic Resonance Imaging, Paclitaxel, Pemetrexed, Positron Emission Tomography, Therapeutic Conventional Surgery
Biological · Procedure · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
46
States / cities
Jonesboro, Arkansas • Tampa, Florida • Boise, Idaho + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 28, 2026, 7:37 PM EDT
Completed Phase 3 Interventional Results available

A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes

NCT02681094
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Inadequate Glycaemic Control
Interventions
Dapagliflozin, Placebo for Dapagliflozin, Saxagliptin, Placebo for Saxagliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
905 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
48
States / cities
Saraland, Alabama • Fresno, California • Harbor City, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 28, 2026, 7:37 PM EDT
Completed Not applicable Interventional Results available

Improving ADHD Teen Driving

NCT02848092
View directory record Official record
Conditions
Attention Deficit Disorder, Attention Deficit Disorder With Hyperactivity
Interventions
FOCAL+, Rules of The road
Behavioral · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
16 Years to 19 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 28, 2026, 7:37 PM EDT
Terminated Not applicable Interventional Results available

Effectiveness of the Quotient® ADHD Assessment in a System of Care

NCT02094612
View directory record Official record
Conditions
Attention Deficit and Disruptive Behavior Disorders, Attention Deficit Disorder With Hyperactivity
Interventions
Quotient®, Usual Clinic ADHD Care
Device · Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
6 Years to 12 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Folsom, California • Roseville, California • Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Oct 28, 2026, 7:37 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Screening Brain MRI in High School Football: Does the Guardian Cap Reduce the Risk of Traumatic Brain Injury

NCT02757053
View directory record Official record
Conditions
Brain Concussion, Brain Injuries, Diffuse Axonal Injury, Athletic Injuries, Injury, Brain, Traumatic
Interventions
Guardian Cap
Device
Lead sponsor
Mosaic Life Care
Other
Eligibility
12 Years to 20 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Saint Joseph, Missouri
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 28, 2026, 7:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Use of a Prokinetic Agent as an Adjunct to Thrice Weekly Bowel Care After SCI

NCT04671030
View directory record Official record
Conditions
Spinal Cord Injuries, Constipation, Neurogenic Bowel
Interventions
Neostigmine and Glycopyrrolate, Iontophoresis
Drug · Device
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 30, 2021 · Synced Oct 28, 2026, 7:37 PM EDT
Completed Phase 2 Interventional

Home Based Treatment for Drug Use in Early Adolescents

NCT00280228
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder, Conduct Disorder, Substance Abuse
Interventions
Adolescent Skills Parent Management Parent-Adol Negotiation, Treatment as Usual
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
11 Years to 14 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 26, 2011 · Synced Oct 28, 2026, 7:37 PM EDT
Recruiting Phase 3 Interventional

A Study of Depemokimab in Participants of 6 to 11 Years of Age

NCT07671001
View directory record Official record
Conditions
Asthma
Interventions
Depemokimab
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Years to 11 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Mobile, Alabama • Colorado Springs, Colorado • Watertown, South Dakota
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 28, 2026, 7:37 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

NCT06385080
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Amivantamab, Pembrolizumab, Paclitaxel, Carboplatin
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
15
States / cities
La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 28, 2026, 7:37 PM EDT
Completed Not applicable Interventional

Organizational Skill Training (OST) in Schools

NCT02663986
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
Organizational Skills Training (OST) Intervention
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
8 Years to 11 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 28, 2026, 7:37 PM EDT
Completed Phase 1 Interventional

An Open-label Study Investigating the Disposition and QT/QTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 µCi)

NCT01161836
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Iniparib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Sep 24, 2013 · Synced Oct 28, 2026, 7:37 PM EDT
Completed Phase 3 Interventional Results available

Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment

NCT00614939
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
11
States / cities
Concord, California • Sacramento, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 19, 2011 · Synced Oct 28, 2026, 7:37 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Investigate Recovery From COVID-19 With C21 in Adult Subjects

NCT04880642
View directory record Official record
Conditions
COVID-19
Interventions
C21, Placebo
Drug
Lead sponsor
Vicore Pharma AB
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Orange, California • Winfield, Illinois • Fort Wayne, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 28, 2026, 7:37 PM EDT
Completed Phase 3 Interventional Results available

A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.

NCT02072824
View directory record Official record
Conditions
Partial Onset Seizures
Interventions
Pregabalin Dose Level 1, Pregabalin Dose Level 2, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
1 Month to 3 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
5
States / cities
Orlando, Florida • Tampa, Florida • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 28, 2026, 7:37 PM EDT
Completed Phase 3 Interventional Results available

Sleep and Tolerability Study: Comparing the Effects of Adderall XR and Focalin XR

NCT00393042
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Dexmethylphenidate, Mixed Amphetamine Salts, ER, placebo
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
9 Years to 17 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Chicago, Illinois • Northbrook, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 28, 2026, 7:37 PM EDT
Recruiting Phase 1 Interventional

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

NCT06860594
View directory record Official record
Conditions
Astrocytoma, IDH-Mutant, Grade 2, Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant, Recurrent Adult Diffuse Midline Glioma, H3 K27-Mutant, Recurrent Astrocytoma, IDH-Mutant, Recurrent Astrocytoma, IDH-Mutant, Grade 3, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype
Interventions
Biospecimen Collection, Computed Tomography, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Triapine
Procedure · Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
43
States / cities
Duarte, California • Irvine, California • La Jolla, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 28, 2026, 7:37 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD

NCT02956122
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
GLASSIA, methylprednisolone or equivalent steroid, Albumin
Biological · Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Oct 28, 2026, 7:37 PM EDT
Completed Phase 1 Interventional

A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

NCT04538794
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
CDX-0159, Normal Saline
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Birmingham, Alabama • Gilbert, Arizona • Sarasota, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 28, 2026, 7:37 PM EDT